ClinicalTrials.Veeva

Menu

A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration

University of California San Francisco (UCSF) logo

University of California San Francisco (UCSF)

Status and phase

Completed
Phase 4

Conditions

Frontotemporal Lobar Degeneration

Treatments

Drug: Memantine

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT00187525
NAM-02A

Details and patient eligibility

About

This is a 52-week, multicenter, open label trial of memantine (Namenda) for frontotemporal lobar degeneration (FTLD). The goal is to determine the safety and tolerability of this FDA-approved medication for Alzheimer's Disease in patients with FTLD. Secondary outcome measures include cognitive batteries, rating scales for activities of daily living and neuropsychiatric symptoms. All patients receive the FDA-approved dose of this medication for Alzheimer's disease.

Sex

All

Ages

40 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Neary et al. Criteria for Frontotemporal Lobar Degeneration
  • Age 40 -80
  • CDR < 3 or MMSE > 15
  • English Speaking
  • Study Partner

Exclusion criteria

  • Concurrent use of antipsychotic drugs or acetylcholinesterase inhibitors

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems